Scotiabank Analyst Maintains 'Buy' Rating for Amgen with $450 Target
Scotiabank analyst Louise Chen has reaffirmed her 'buy' rating for Amgen (AMGN.US), leaving its target price unchanged at $450.
Chen's success rate over the past year is 53.4%, with a total average return of 7.1% according to TipRanks data.
TipRanks provides analysis and calculates the performance of financial analysts, including Chen's ratings for Amgen.